Correction to: CRISPR-Cas, a robust gene-editing technology in the era of modern cancer immunotherapy.
Seyed Mohammad MiriElham TafsiriWilliam Chi Shing ChoAmir GhaemiPublished in: Cancer cell international (2020)
An amendment to this paper has been published and can be accessed via the original article.
Keyphrases